
Please try another search
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.
Name | Age | Since | Title |
---|---|---|---|
Michael Weinfeld | - | 2024 | Advisory Board Member |
Steven Jones | - | 2025 | Senior Scientific Advisor |
James Orbinski | - | 2025 | Member of Scientific & Clinical Advisory Board |
Maximilian Justus | 34 | 2024 | Independent Director |
Graydon Bensler | 33 | 2024 | Director |
Richard Heinzl | 61 | 2024 | Independent Director |
Islam Mohamed | - | 2025 | Chairman of Scientific & Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review